GlassScriptPhysician profile
Paul Jasper Capriotti
NPI 1609859271
$2,617.31
in general payments reported to CMS, 2019-2025
21 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $36.59 · 2021: $12.50 · 2022: $321 · 2023: $552 · 2024: $554 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $389.27 | 2022-2025 | Ingrezza |
| Abbvie INC. | $315.25 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $265.95 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $246.10 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.66 | 2023-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Allergan, INC. | $167.46 | 2019 | |
| Supernus Pharmaceuticals, INC. | $128.72 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $91.79 | 2023-2025 | Quviviq, Quviviq |
| Corium, LLC | $84.06 | 2022-2023 | Azstarys |
| Alkermes, INC. | $82.21 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $78.71 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $60.19 | 2019-2022 | |
| Lundbeck LLC | $56.03 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $47.99 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $42.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.49 | 2019-2020 | |
| Bausch Health US, LLC | $37.51 | 2019-2024 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $37.16 | 2025 | Cobenfy |
| Indivior INC. | $27.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Capriotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.